Back

Liraglutide and empagliflozin – An evaluation of benefits.

27 August 2017 (14:22 - 14:45)
Organised by:
Congress Presentation Part of: Treatment of type 2 diabetes - Important new aspects for the cardiologist Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Associate Professor Thomas Andersen Schmidt

Bispebjerg University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Treatment aims of glucose lowering drugs in patients with type 2 diabetes
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Rethinking the appraisal and approval of drugs for type 2 diabetes.
Professor A. Tsapas (Thessaloniki, GR)
Slides Video
Presentation thumbnail
Is type 2 diabetes a category error - How about treating the elderly?
Professor G. Schernthaner (Vienna, AT)
Slides Video

Access the full session

Session thumbnail
Treatment of type 2 diabetes - Important new aspects for the cardiologist

The Event

Event poster

ESC Congress 2017

27 August 2017 14:22 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results
29 June 2021
thumbnail
Webinar
Clinical trials and highlights from ACC 2024
10 April 2024
thumbnail
Congress Presentation
The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers
27 August 2021
thumbnail
Congress Presentation
All diabetic patients should be treated with GLP1 and/or GIP agonists.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources